NeoRecormon Safe In Treating Anaemia In Cancer Patients

Armen Hareyan's picture
Advertisement

A new meta-analysis of all 12 prospective, randomised, controlled studies in 2,301 cancer patients shows that treating anaemia with NeoRecormon (epoetin beta) has no negative impact on survival, tumour progression or deaths caused by blood clots, when used within its approved indications.

Share this content.

If you liked this article and think it may help your friends, consider sharing or tweeting it to your followers.
Advertisement